POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with BRAF V600-mutant melanoma with brain metastasis.
Saved in:
| Title: | POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with BRAF V600-mutant melanoma with brain metastasis. |
|---|---|
| Authors: | Menzies AM; Melanoma Institute Australia, NSW, Australia, and The University of Sydney, Sydney, Australia.; Royal North Shore and Mater Hospitals, The University of Sydney, Sydney, Australia., Long GV; Melanoma Institute Australia, NSW, Australia, and The University of Sydney, Sydney, Australia.; Royal North Shore and Mater Hospitals, The University of Sydney, Sydney, Australia., Kohn A; Division of Hematology/Medical Oncology, School of Medicine, Oregon Health Sciences University, Portland, Oregon, USA., Tawbi H; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Weber J; Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, New York, USA., Flaherty K; Massachusetts General Cancer Center, Massachusetts General Hospital, Boston, Massachusetts, USA., McArthur GA; Sir Peter MacCallum Department of Oncology, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, Victoria, Australia., Ascierto PA; Unit of Melanoma Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy., Pfluger Y; Alexander Fleming Institute, Buenos Aires, Argentina., Lewis K; Medical Oncology, University of Colorado, Health Center, Denver, Colorado, USA., Tsai KK; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA., Hamid O; The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate Los Angeles, California, USA., Prenen H; Oncology Department, University Hospital Antwerp, Antwerp, Belgium., Fein L; Alexander Fleming Institute, Buenos Aires, Argentina., Wang E; Formerly Pfizer, New York, New York, USA., Guenzel C; Formerly Pfizer, New York, New York, USA., Zhang F; Formerly Pfizer, New York, New York, USA., Kleha JF; Formerly Pfizer, New York, New York, USA., di Pietro A; Pfizer Srl, Milan, Italy., Davies MA; Department of Melanoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. |
| Source: | Neuro-oncology advances [Neurooncol Adv] 2024 Mar 18; Vol. 6 (1), pp. vdae033. Date of Electronic Publication: 2024 Mar 18 (Print Publication: 2024). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 101755003 Publication Model: eCollection Cited Medium: Internet ISSN: 2632-2498 (Electronic) Linking ISSN: 26322498 NLM ISO Abbreviation: Neurooncol Adv Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2632-2498 |
|---|---|
| DOI: | 10.1093/noajnl/vdae033 |
